- BioPharm International-04-01-2003
 - Volume 16
 - Issue 4
 
Virus Inactivation in the 1990s and into the 21st Century
by Gail Sofer, BioReliance Dorothy C. Lister, and Jeri Ann Boose Smallest of the microorganisms, viruses depend on other cells ? like those used by biopharmaceutical manufacturers ? for reproduction. And viruses and drug products are idiosyncratic: Both the inactivation process and the product strongly influence the successful outcome. In this conclusion to the virus inactivation series, model ivruses are used to represent single- and double-stranded DNA and RNA viruses, to enable you to reach conclusions about effective inactivation methods for a range of viruses.
Articles in this issue
over 22 years ago
Getting Ready for Risk-Based GMPsover 22 years ago
GMP Issues: Breaking Groundover 22 years ago
Guest Editorial: Benchmarking Biotechover 22 years ago
Optimized Nutrient Additives for Fed-Batch Culturesover 22 years ago
Inside Washington: GMP Progress ReportNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

